Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mirus Bio LLC is currently dealing with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner in 1 distinct art unit. The company's active prosecution is limited to this single technical evaluation, suggesting a highly focused approach to its biotechnology patent portfolio. Having only 1 pending office action allows the company to focus its arguments on the specific technical issues raised by the examiner.
The busiest examiner for the portfolio is BORALSKY, LUKE ALAN, who holds 1 busiest examiner pending action. Because there is only 1 pending action total, this examiner is the sole authority currently reviewing the company's patent claims. Practitioners should focus on the specific art unit standards applied by this examiner. Since the prosecution involves 1 distinct examiner and 1 distinct art unit, the applicant can develop a targeted response that directly addresses the examiner's concerns to move the application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351213 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | BORALSKY, LUKE ALAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351213 | CATIONIC CYCLIC AMINE AND AMPHIPATHIC TRANSFECTION REAGENTS | BORALSKY, LUKE ALAN | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMirus Bio LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Luke Alan Boralsky has the most, with 1 of Mirus Bio LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.